Monday, November 18, 2024
- 10:30AM-12:30PM
-
Abstract Number: 2048
Prognostic Value of Bronchoalveolar Lavage in CTD-related Interstitial Lung Disease: An Observational Study
Miscellaneous Rheumatic & Inflammatory Diseases Poster III- 10:30AM-12:30PM
-
Abstract Number: 2451
Prognostic Value of Functional Outcomes in a Italian Multicentric Cohort of Early SSc-ILD Patients
Systemic Sclerosis & Related Disorders – Clinical Poster III- 10:30AM-12:30PM
-
Abstract Number: 2470
Progression Patterns in Systemic Sclerosis – Associated Interstitial Lung Diseases
Systemic Sclerosis & Related Disorders – Clinical Poster III- 10:30AM-12:30PM
-
Abstract Number: 2396
PROMISing Outcomes: Understanding the Concordance Between Provider-assessment and Patient-reported Disease Activity in SLE
SLE – Diagnosis, Manifestations, & Outcomes Poster III- 10:30AM-12:30PM
-
Abstract Number: 2065
Proposed Pathways Involved in the Pathogenesis of Juvenile Dermatomyositis (JDM)
Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III- 10:30AM-12:30PM
-
Abstract Number: 2310
Prospective Evaluation of Pulmonary Involvement in Patients with Primary Sjögren’s Disease, Using Pulmonary Function Tests and High Resolution Computed Tomography, Reveals High Prevalence of Subclinical Interstitial Lung Disease, Along with Small Airways Disease
Sjögren's Syndrome – Basic & Clinical Science Poster II- 10:30AM-12:30PM
-
Abstract Number: 2193
Prospective Evaluation of Reactogenicity and Safety Following COVID-19 Vaccination in Children with a History of MIS-C
Pediatric Rheumatology – Clinical Poster III- 10:30AM-12:30PM
-
Abstract Number: 1825
Proteomic and Transcriptomic Analysis Reveal Elevated Senescent Signature in Systemic Sclerosis Fibrosis
Systemic Sclerosis & Related Disorders – Basic Science Poster II- 10:30AM-12:30PM
-
Abstract Number: 2081
Proteomic Profiling of Urine Reveals Biomarker Candidates for Idiopathic Inflammatory Myopathies
Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III- 10:30AM-12:30PM
-
Abstract Number: 2332
PsAID12 Thresholds Defining Disease Impact Severity in Psoriatic Arthritis Developed in an Observational Setting Showed Higher Sensitivity but Lower Specificity Than Those Developed in a Randomized Controlled Trial Setting
SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster III- 10:30AM-12:30PM
-
Abstract Number: 1883
Psoriatic Arthritis Flare Incidence, Definitions and Risk Factors: A Systematic Review
Epidemiology & Public Health Poster III- 10:30AM-12:30PM
-
Abstract Number: 2234
Pulmonary Damage Biomarkers and Progression of Rheumatoid Arthritis-associated Interstitial Lung Disease in a Prospective Longitudinal Cohort
RA – Diagnosis, Manifestations, & Outcomes Poster III- 10:30AM-12:30PM
-
Abstract Number: 2064
Quantifying Cutaneous Dermatomyositis: A Novel 3D Image-based Approach
Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III- 10:30AM-12:30PM
-
Abstract Number: 1972
Quantifying Sjogren’s Disease Burden: UHFUS Evaluation of the Number and Severity of Involved Exocrine Gland